Pharmaceutical Technology - April 2023

Pharmaceutical Technology- April 2023

Issue link: https://www.e-digitaleditions.com/i/1497323

Contents of this Issue

Navigation

Page 21 of 52

22 Pharmaceutical Technology ® The Real Message Behind Commercial mRNA Products April eBook 2023 PharmTech.com SCIENCEDISPL AY - STOCK.ADOBE.COM F or messenger RNA (mRNA) therapeutics and vaccines formulated as lipid nanoparticles (LNPs), the excipients receiving the most at- tention are the encapsulating lipids. While these compounds are crucial to the stability and deliv- ery of mRNA-LNPs, the non-lipid excipients also play crucial roles in the function of final drug products. They impact the morphology and stability of these delivery systems, which in turn affects in vivo perfor- mance and the overall usefulness of mRNA drugs de- veloped using nanoparticle technology. A number of non-lipid excipients needed Non-lipid excipients used to formulate mRNA-LNP products include solvents, salts, and sugars/cryopro- tectants, according to David Jung, senior manager RD&I, nucleic acids at Evonik. Overall, these excipients serve the function of controlling the pH during the ini- tial mixing and formation of the particle and ensuring stability upon storage of the material, he notes. More specifically, rapid mixing is the predominant technique for lipid nanoparticle–mRNA formulations: an ethanol phase (lipid components) and an aqueous phase (mRNA molecules, usually in acetate or citrate buffers) are mixed under specific conditions (pH and f low rate), explains Luca Bruno, segment marketing manager, MilliporeSigma, the Life Science business of Merck KGa A, Darmstadt, Germany. Rapid mix- ing, he adds, allows scalability and reproducibility of mRNA-LNP formulation. Organic solvents and residual components are then removed by ultrafiltration. The mRNA-LNP drug sub- stance is then formulated using a more physiological buffer, typically tris(hydroxymethyl)aminomethane- Excipients Impact Stability in mRNA-LNP Formulations Cynthia A. Challener, PhD has been a freelance technical writer for over 20 years and contributes regularly to BioPharm International and Pharmaceutical Technology. Lipids aren't the only important ingredients influencing stability and in vivo performance.

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - April 2023 - Pharmaceutical Technology- April 2023